25.01.2012

Atlanta – The Center for Global Health

Down South - Atlanta has a healthy biosciences community with a rich mix of pharmaceutical, medical devices, diagnostic and medical supply companies; contract laboratory, preclinical and clinical research organizations; and world-class public and private institutions and universities. Atlanta's Bioscience Cluster more03.11.2011

Global Pharma to Pump Cash Into Russia

  Viiv Healthcare, a GlaxoSmithKline and Pfizer joint venture, will start manufacturing HIV medicines in Russia in partnership with local drugmaker Binnopharm. Agreeing a local partnership is a way for international drug companies to secure guaranteed sales in Russia, which wants to reduce dependence on imported drugs. Global drugmakers have pledged at least $1 billion in investments in Russian manufacturing, packaging and research and development. more21.09.2011

Sanofi Pasteur Acquires Worldwide License For Acne Vaccine, Treatment

Sanofi Pasteur, the vaccines division of Sanofi-Aventis, announced a research and development collaboration with the University of California, San Diego on an immunological approach to acne prevention and treatment targeting the specific neutralization of Propionibacterium acnes factors in inflammation. The financial terms of the agreement were not disclosed. more28.07.2011

Sanofi-Aventis Q2 Profit Slips

Sanofi-Aventis reported a 13.2% decline in its second-quarter business net income to €2.15 billion  from €2.48 billion last year. Business earnings per share were €1.64, down 13.7% from €1.90 in the 2010 second quarter. At constant exchange rates, business earnings per share decreased by 7.4%. more14.04.2011

Sanofi Weighing Options For U.S. Dermatology Unit

Sanofi-Aventis said it was considering "strategic alternatives" for its U.S. dermatology business, as it seeks to refocus its business on growth areas such as diabetes and cancer treatments. The company's comment came after Bloomberg News published a story on Wednesday on how Sanofi was seeking to sell the unit, which the report said could be valued around €300 million. more11.04.2011

Sanofi Completes Genzyme Takeover

Sanofi-Aventis said it has completed its takeover of U.S. biotechnology company Genzyme. The companies agreed in February on a deal worth about $20.1 billion. The acquisition gives Sanofi access to Genzyme's business in treating rare diseases and is expected to help the company combat sales erosion from drugs facing cheap generic competition. more04.04.2011

Sanofi Says Gains Control Of Genzyme

French drugmaker Sanofi-Aventis completed its improved $20.1 billion offer for Genzyme allowing it to begin merging the U.S. biotech into its business and add rare diseases to its growth areas. more30.03.2011

Sanofi CVRs Tied To Genzyme May Start Trading April 4

Certificates related to Sanofi-Aventis's $20.1 billion acquisition of U.S. biotech firm Genzyme could begin trading on Nasdaq as soon as April 4, depending on the outcome of its tender offer. The French drugmaker said on Tuesday that the U.S. Securities and Exchange Commission (SEC) had cleared the trading of contingent value rights (CVR) under the ticker. more24.03.2011

Chris Viehbacher: Sanofi to Grow Animal Health Through Bolt-On Buys

French drugmaker Sanofi-Aventis plans to expand its Merial animal health business through bolt-on acquisitions, its chief executive said on the sidelines of a conference on Wednesday. "Bolt-ons are going to be easier" than large acquisitions, Chris Viehbacher said. This was because of competition issues in the increasingly consolidating industry. more22.03.2011

Merck, Sanofi Cancel Planned Animal-Health JV

Merck & Co and Sanofi-Aventis have terminated their agreement to form a new animal health joint venture. Regarding the reason for the termination, the companies cited the increasing complexity of implementation and the length of time necessary for the worldwide regulatory review process. more